STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £55.86m
- £68.28m
- $49.70m
Shield Therapeutics - Q1 2025 Trading Update
Shield Therapeutics - PDMR Transaction Notification
Shield Therapeutics - Grant of Share Options
Brief: Shield Therapeutics Says FY Group Revenues Ahead Of Expectations At $32.2 Mln
Shield Therapeutics - Unaudited full year trading update
Brief: Shield Therapeutics Appoints Anders Lundstrom As CEO
Shield Therapeutics - Anders Lundstrom appointed CEO
Shield Therapeutics - Results of RetailBook Offer
Shield Therapeutics - RetailBook Offer
Brief: Shield Therapeutics Reiterates Guidance To Meet $31.5 Mln Revenue Target For 2024
Shield Therapeutics - Business Update
Shield Therapeutics - Q3 Trading Update
Brief: Shield Therapeutics Says All Primary Endpoints Met In Phase 3 Paediatric Study
Shield Therapeutics - Results from Phase 3 paediatric study
Shield Therapeutics - Interim results
Shield Therapeutics - Notice of interim results
Brief: Shield Therapeutics CEO Greg Madison Steps Down
Shield Therapeutics - Unaudited Q2 2024 Trading Update
Shield Therapeutics - Directorate Change